Articles
BitMine Immersion Technologies Advances Its Ethereum Holdings and Staking Ambitions
Firm Increases Control Over Ethereum, Prepares for Launch of MAVAN Staking Network in 2026
BitMine Immersion Technologies Inc has significantly bolstered its cryptocurrency portfolio, now controlling over 3.4% of all circulating Ethereum and...
Triata Capital’s Substantial Investment in ACM Research Highlights Strong Confidence in Semiconductor Equipment Sector
Hong Kong-based Fund Elevates ACM Research to Fourth-Largest Holding Amid Impressive Stock Performance and Robust Revenue Growth
Triata Capital Ltd has notably increased its position in ACM Research, acquiring 413,000 additional shares in Q3, raising its stake to two million sha...
Forecasting Bitcoin’s Value in 2030: Examining the Potential Growth of a $1 Investment
Assessing long-term price projections and risks for Bitcoin over the next decade
Bitcoin has displayed significant volatility in 2025, erasing its gains and currently sitting down 6% for the year as of late December. Despite this, ...
Duke University Implements Major Budget Cuts Through Buyouts and Facility Closures Amid Federal Funding Reductions
Institution undertakes a $364 million cost-saving initiative focusing on personnel and operational expenses in response to diminished federal support
In response to significant reductions in federal funding affecting both its academic and health system operations, Duke University has launched a comp...
Josh Allen to Rest in Season Finale, Easing Pressure Before Playoffs
Buffalo Bills' Quarterback to Sit Out Most of Week 18 Game to Recover from Injuries and Fatigue
Buffalo Bills quarterback Josh Allen is set to take a well-deserved break during the team's final regular-season game against the New York Jets. After...
SELLAS Life Sciences Shares Rally Following Key Update on AML Maintenance Therapy Trial
Advancements in the Phase 3 REGAL Trial Drive Investor Interest in SELLAS Life Sciences Group Inc.
Shares of SELLAS Life Sciences Group Inc have experienced a notable increase after the company provided new information related to its Phase 3 REGAL t...
Understanding States Without Income Tax and Their Fiscal Implications
An in-depth look at the eight U.S. states that forgo state income tax and what that means for residents
In the United States, state-level income tax is a common obligation for residents, but eight states stand out by not imposing this tax. This article e...
AXT Inc. Shares Retreat Following $87 Million Public Offering Pricing
Market reacts cautiously as AXT Inc. announces utilization plans for capital raise
AXT Inc. recently finalized the pricing of a public offering amounting to $87 million, issuing over seven million shares at $12.25 each. Following thi...
PayPal: A 2026 Position Trade Backed by Cash Flow and a New Banking Push
Long idea — entry 57–61, stop 52, targets 75 / 90; catalyst-rich trade into 2026
PayPal is cheap-ish relative to where it traded in 2025, generates strong operating cash flow, and is pushing into deeper financial services with a ba...
Zeta Global: A SMID-Cap Rotation Trade Into AI-Driven Revenue Re-Acceleration
Take a tactical long: fundamentals turning, cash flow improving, and a manageable capital structure — but watch legal headlines and execution risk.
Zeta Global (ZETA) looks like an attractive SMID-cap rotation trade. Recent quarters show accelerating top-line, operating income inflection, and stea...
Nu Holdings' Growth Trajectory and Valuation Ahead of Q4 Earnings
An in-depth analysis of Nu holdings’ expanding fintech presence in Latin America and its investment prospects before its upcoming earnings report
Nu Holdings, a leading fintech operator in Latin America, has exhibited rapid growth in customers, revenue, and profitability, achieving notable marke...
Ultragenyx Pharmaceuticals Faces Share Price Collapse Following Phase 3 Setrusumab Trial Failures
Significant declines in Ultragenyx's stock price follow disappointing late-stage clinical trial results for osteogenesis imperfecta treatment and analyst downgrades
Ultragenyx Pharmaceuticals experienced a severe drop in its stock value after announcing that its Phase 3 clinical trials for setrusumab failed to mee...